147.86
price down icon0.85%   -1.27
pre-market  시장 영업 전:  146.00   -1.86   -1.26%
loading

Biogen Inc 주식(BIIB)의 최신 뉴스

pulisher
Oct 29, 2025

Analyzing Biogen Inc. with multi timeframe charts2025 Top Gainers & Daily Volume Surge Signals - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Biogen (BIIB): Reassessing Valuation After Recent Share Price Momentum - simplywall.st

Oct 29, 2025
pulisher
Oct 29, 2025

United States Biotechnology Market 2025: Industry - openPR.com

Oct 29, 2025
pulisher
Oct 29, 2025

Why Biogen Inc. (IDP) stock stays on top picksWeekly Investment Summary & Safe Capital Growth Tips - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

PEGylated Proteins Market See Incredible Growth 2025-2032 | Biogen Inc, Pfizer Inc, and UCB S.A. - openPR.com

Oct 29, 2025
pulisher
Oct 29, 2025

Is Biogen Inc. stock a safe buy before earnings2025 Geopolitical Influence & Detailed Earnings Play Alerts - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

United States Biosimilars Market is expected to reach US$ 171.79 - openPR.com

Oct 29, 2025
pulisher
Oct 29, 2025

Nisa Investment Advisors LLC Has $6.39 Million Stock Position in Biogen Inc. $BIIB - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Brighton Jones LLC Purchases New Stake in Biogen Inc. $BIIB - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Is Biogen Inc. stock a top momentum playJuly 2025 Chart Watch & Weekly Watchlist for Hot Stocks - newser.com

Oct 29, 2025
pulisher
Oct 28, 2025

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect - The Globe and Mail

Oct 28, 2025
pulisher
Oct 28, 2025

Biogen Seeks To Stand Out in Lupus With New Anti-CD40L Data - BioSpace

Oct 28, 2025
pulisher
Oct 28, 2025

Will Biogen Inc. (IDP) stock benefit from commodity supercycleJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Volatility clustering patterns for Biogen Inc.Earnings Risk Summary & Fast Entry High Yield Tips - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will Biogen Inc. (IDP) stock benefit from sector leadershipJuly 2025 Selloffs & Safe Capital Growth Tips - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Sumitomo Mitsui Trust Group Inc. Decreases Stake in Biogen Inc. $BIIB - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

Key metrics from Biogen Inc.’s quarterly dataPortfolio Risk Summary & Technical Pattern Alert System - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Biogen Inc.’s volatility index tracking explainedMarket Performance Report & Verified Short-Term Plans - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Historical volatility pattern of Biogen Inc. visualizedLong Setup & Weekly Top Gainers Alerts - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

United States Inflammatory Bowel Disease Market is expected - openPR.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will Biogen Inc. stock gain from strong economyJuly 2025 Earnings & Fast Gaining Stock Reports - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

Institutional scanner results for Biogen Inc.July 2025 Rallies & Technical Analysis for Trade Confirmation - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is Biogen Inc. (IDP) stock a buy on weaknessJuly 2025 Sector Moves & Consistent Profit Trade Alerts - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

How to escape a deep drawdown in Biogen Inc.Weekly Loss Report & Daily Chart Pattern Signal Reports - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Felzartamab Trial: A New Hope for Kidney Transplant Patients - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s PMN Study: A Potential Game-Changer for Kidney Disease Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Litifilimab Study: A Promising Step for Lupus Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s New Study on Felzartamab: A Potential Game-Changer for Kidney Transplant Patients - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Study on Diroximel Fumarate: A Closer Look at Pregnancy Outcomes - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Litifilimab Study: A Potential Game-Changer in Lupus Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Nusinersen Study: Exploring Pregnancy Outcomes in SMA Patients - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Innovative Approach in SMA Treatment: ThecaFlex DRx™ System Study Update - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Innovative Approach to SMA Treatment: A Study Update - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s New Study on Omaveloxolone: A Potential Game-Changer for Friedreich’s Ataxia - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s BIIB142 Study: A New Chapter in Drug Safety Evaluation - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen and Denali’s New Study on LRRK2-Associated Parkinson’s Disease: What Investors Need to Know - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen, Inc. Experiences Valuation Adjustment Amidst Market Performance Challenges - Markets Mojo

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Pregnancy Exposure Study: Implications for MS Treatment Market - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Zuranolone Study: A Potential Game-Changer for Postpartum Depression Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Omaveloxolone Study: Assessing Safety During Pregnancy and Lactation - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s New MS Study: A Potential Game-Changer for Investors? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen’s Omaveloxolone Study: A Closer Look at Long-Term Safety for Friedreich’s Ataxia - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow - Morningstar

Oct 27, 2025
pulisher
Oct 27, 2025

Health Canada Grants Authorization for LEQEMBI® (lecanemab) for the Treatment of Early Alzheimer’s Disease - Cantech Letter

Oct 27, 2025
pulisher
Oct 27, 2025

Health Canada Grants Authorization for LEQEMBI® (lecanemab) for the Treatment of Early Alzheimer's Disease - Newswire Canada

Oct 27, 2025
pulisher
Oct 27, 2025

AustralianSuper Pty Ltd Has $92.86 Million Stake in Biogen Inc. $BIIB - MarketBeat

Oct 27, 2025
pulisher
Oct 27, 2025

OVERSEA CHINESE BANKING Corp Ltd Cuts Stock Position in Biogen Inc. $BIIB - MarketBeat

Oct 27, 2025
pulisher
Oct 27, 2025

Using portfolio simulators with Biogen Inc. includedMarket Performance Report & Free Safe Entry Trade Signal Reports - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

How Biogen Inc. (IDP) stock behaves in tightening cycles2025 Market Sentiment & Risk Managed Trade Strategies - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Sector ETF performance correlation with Biogen Inc.Quarterly Investment Review & Entry and Exit Point Strategies - newser.com

Oct 27, 2025
drug_manufacturers_general SNY
$50.68
price down icon 0.74%
drug_manufacturers_general PFE
$24.29
price down icon 0.86%
$118.50
price up icon 0.53%
$291.77
price down icon 0.11%
drug_manufacturers_general NVO
$51.37
price down icon 1.31%
drug_manufacturers_general MRK
$86.58
price down icon 0.52%
자본화:     |  볼륨(24시간):